Wt1 trio peptide-based cancer vaccine for rare cancers expressing shared target wt1

HIGHLIGHTS

• who: Yusuke Oji et al. from the Department of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine, Osaka, Japan have published the paper: WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1, in the Journal: Cancers 2023, 15, 393. of 30/Nov/2022
• what: No standard treatment has been established for most Here the authors report a clinical trial of a biweekly tri-peptide-based vaccine for recurrent or advanced Due to the insufficient number of patients available for a traditional clinical trial the trial was designed for . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.